Exelixis
Treatment Decisions When Initiating a Tyrosine Kinase Inhibitor and Dose Management to Help Optimize Outcomes
Please see accompanying full Prescribing Information
This program is sponsored by Exelixis, Inc., and was developed in conjunction with Dr. Strauss and Dr. Hanna, who received a fee for participating in this program. Dr. Strauss' and Dr. Hanna's comments reflect their opinions and are not intended to constitute medical advice for individual patients. The case study details presented are hypothetical. Individual results may vary.
CA-3459
©2024 Exelixis, Inc.
Comments are disabled for this content.
